The American Heart Association (AHA) has released a new scientific statement highlighting the strong connection between cardiovascular diseases and an increased risk of cognitive impairment and dementia. Conditions such as heart failure, atrial fibrillation, and coronary heart disease can directly impact brain function, leading to cognitive decline. Maintaining heart health from a young age is crucial in preventing cardiovascular diseases, protecting brain function, and reducing the risk of cognitive decline later in life.
Research suggests that the blood thinner heparin may delay the onset of Alzheimer’s disease by interfering with harmful protein interactions in the brain. Previous studies have shown that individuals with atrial fibrillation who were treated with direct oral anticoagulants had a lower risk of developing dementia compared to those treated with warfarin. The new study found that people undergoing heparin treatment developed Alzheimer’s symptoms up to 2 years later than expected, indicating a potential protective benefit of this common anticoagulant.
Researchers analyzed medical records from two large health systems, Mount Sinai Health System and Columbia University Medical Center, to compare patients who had received heparin to those who had not. While all study participants eventually received an Alzheimer’s diagnosis, those who received heparin were diagnosed about 1 year later on average. The findings suggest that heparin therapy may offer some protection against Alzheimer’s disease, particularly in individuals at higher genetic risk of developing the condition.
The study’s senior author, Eric M. Reiman, MD, explained that the findings do not have immediate implications for the use of current heparin formulations in Alzheimer’s treatment. However, the study could inform the development of new disease-modifying treatments for Alzheimer’s, especially in carriers of the APOE4 gene, the major genetic risk factor for the disease. The research highlights the potential for using large electronic health record data sets to evaluate the effects of different drugs in treating and preventing Alzheimer’s disease.
While more research is needed to confirm the efficacy of heparin in protecting brain health, the study suggests that targeting harmful protein interactions in the brain could lead to the development of new drugs for Alzheimer’s disease. Neurologist Clifford Segil, DO, emphasized the need for further studies to determine if heparin use can reduce the risk of stroke-related dementias or vascular dementia, in addition to Alzheimer’s. The study showcases the potential of using existing health data to explore new treatments and target biological changes in the development of innovative drug therapies.
